In a first, the FDA has approved an inhibitor of hypoxia-inducible factor-2α. 
The drug is also the first approved to treat von Hippel-Lindau 
disease-associated renal cell carcinoma, central nervous system 
hemangioblastomas, and pancreatic neuroendocrine tumors.